Resources/
Phil Blog
Phil Blog
Duchesnay USA’s Women’s Healthcare Launches on Phil
SAN FRANCISCO--(BUSINESS WIRE)--Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced that Duchesnay USA’s Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments, is now available to be prescribed via its patient access platform. It is not known if Bonjesta® is safe and effective in women with severe nausea and vomiting of pregnancy, a condition called hyperemesis gravidarum. The most common side effect of Bonjesta® is drowsiness.Phil’s customizable platform helps patients receive and refill medicines quickly, easily and affordably while giving life science companies unprecedented end-to-end visibility into the prescription life cycle
Policy Updates Drug Manufacturers Need to Know
The pharmaceutical industry is one of the most highly regulated industries in the United States. Despite many legal and regulatory obstacles, the U.S. has led the world in the number of new chemical and biological entity launches since the year 2000
Metrics that matter when measuring your access program
For life science companies, patient support services have become as vital to a brand’s success as efficacy and price. A patient support services program has the potential to help break through barriers to medication access. That’s why it’s crucial to make sure it aligns with your business goals and delivers on your brand objectives while helping patients access their therapy as easily as possible
A distribution Strategy that Optimizes Gross to Net
Downward pressure on net sales is an ongoing problem for pharmaceutical and life sciences companies. It’s crucial to understand the gross-to-net (GNT) challenges that manufacturers are facing and how they can leverage their distribution strategies to optimize GTN. Understanding the challenges surrounding GTN Numerous factors impact a life science company’s GTN, which is the difference between the wholesaler acquisition cost (WAC) – also known as the drug’s list price – and the manufacturer’s net sales
Are Traditional Hub Providers Keeping Pace?
The seismic changes in consumer behavior and expectations brought on by mobile devices and cloud computing seem to have happened overnight, but they’ve been years in the making. The popularity of user-friendly services offered by the likes of Amazon, Uber, and Apple Pay has driven innovation and disruption across industries. The COVID-19 pandemic further accelerated the shift to digital tools, especially in healthcare
Ready to learn more?
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.
